Short answer
Xenon Pharmaceuticals Inc. (XENE) filed an 8-K current report with the SEC on August 6, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item 7.01 (Regulation FD Disclosure), Item EX-99.1 (Exhibit EX-99.1). Q2 and first-half 2026 financial results announced for periods ended June 30, 2026.
Xenon Pharmaceuticals Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Q2 and first-half 2026 financial results announced for periods ended June 30, 2026
- Exhibit 99.1 contains the substantive results and management commentary
- Earnings disclosure gives investors updated visibility into cash resources, operating expenses, and clinical-program funding
Item 7.01 · Regulation FD Disclosure
- Investor communications may contain material information across SEC filings, press releases, calls, company websites, and social media
- Key monitoring channels include @XenonPharma on X, LinkedIn, and investor news releases
- Disclosure expands beyond formal filings, increasing importance of monitoring company communications for market-moving updates
Item EX-99.1 · Exhibit EX-99.1
- Q2 2026 net loss $110.7M versus $84.7M, reflecting accelerated investment in azetukalner and pain programs
- Cash, equivalents and marketable securities $1.245B, supporting operations into 2029 and reducing near-term financing risk
- Azetukalner NDA submission for focal onset seizures remains on track for Q3 2026 after FDA pre-NDA meeting
- Phase 3 neuropsychiatry programs advance, with X-NOVA2 major depressive disorder data expected H1 2027
- R&D expense rose to $99.2M from $75.0M, while shares outstanding reached 96,752,884 plus 2,931,293 pre-funded warrants
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Xenon Pharmaceuticals Inc. 8-K filings
Get the next XENE 8-K as it lands
Follow XENE for push alerts, or ask the research agent what this filing means.